Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18162860 | 0.82 | HIF1A (0.33) | HIF1ATAAR1L3MBTL1CYP19A1 | |
| SCHEMBL16619825 | 0.76 | CYP19A1 (0.59) | HSP90AB1L3MBTL1CYP19A1 | |
| SCHEMBL18028297 | 0.70 | HSP90AB1 (0.70) | HSP90AB1CYP19A1 | |
| SCHEMBL16626918 | 0.69 | ALDH1A1 (0.49) | HSP90AB1MAPTSMN1; SMN2 | |
| SCHEMBL23642697 | 0.68 | MAPT (0.54) | HSP90AB1MAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL18672838 | 0.68 | MAPT (0.54) | HSP90AB1MAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL30191149 | 0.68 | SMN1; SMN2 (0.79) | MAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL138261 | 0.66 | SMN1; SMN2 (0.83) | MAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL20393733 | 0.65 | HSP90AB1 (0.45) | HSP90AB1MAPTSMN1; SMN2LIN28ATDP1 | |
| SCHEMBL16620124 | 0.65 | HSP90AB1 (0.61) | HSP90AB1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603953-B2 | Dendrimer compositions, methods of synthesis, and uses thereof | YANG, Guanghua (FR) | 2017-03-28 | — | — | US | disclosed |
| US-9603953-B2 | Dendrimer compositions, methods of synthesis, and uses thereof | YANG, Guanghua (FR) | 2017-03-28 | — | — | US | disclosed |
| US-20160303261-A1 | DENDRIMER COMPOSITIONS, METHODS OF SYNTHESIS, AND USES THEREOF | SADEG, Nouredine (FR) | 2016-10-20 | — | — | US | disclosed |
| US-20160303261-A1 | DENDRIMER COMPOSITIONS, METHODS OF SYNTHESIS, AND USES THEREOF | SADEG, Nouredine (FR) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303261-A1 | DENDRIMER COMPOSITIONS, METHODS OF SYNTHESIS, AND USES THEREOF | DDOST, CD44, CLTB | HSP90AB1 2051/4885MAPT 324/4885SMN1; SMN2 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.